Show simple item record

dc.contributor.authorCoto Vilcapoma, María Almudena
dc.contributor.authorCastilla Silgado, Juan
dc.contributor.authorFernández García, Benjamín
dc.contributor.authorPinto Hernández, Paola
dc.contributor.authorCipriani, Raffaela ORCID
dc.contributor.authorCapetillo González de Zarate, Estibaliz
dc.contributor.authorMenéndez González, Manuel
dc.contributor.authorÁlvarez Vega, Marco
dc.contributor.authorTomás Zapico, Cristina
dc.date.accessioned2022-08-31T06:42:00Z
dc.date.available2022-08-31T06:42:00Z
dc.date.issued2022-08-17
dc.identifier.citationInternational Journal of Molecular Sciences 23(16) : (2022) // Article ID 9256es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10810/57356
dc.description.abstract[EN] We have previously proposed a radical change in the current strategy to clear pathogenic proteins from the central nervous system (CNS) based on the cerebrospinal fluid (CSF)-sink therapeutic strategy, whereby pathogenic proteins can be removed directly from the CNS via CSF. To this aim, we designed and manufactured an implantable device for selective and continuous apheresis of CSF enabling, in combination with anti-amyloid-beta (Aβ) monoclonal antibodies (mAb), the clearance of Aβ from the CSF. Here, we provide the first proof of concept in the APP/PS1 mouse model of Alzheimer’s disease (AD). Devices were implanted in twenty-four mice (seventeen APP/PS1 and seven Wt) with low rates of complications. We confirmed that the apheresis module is permeable to the Aβ peptide and impermeable to mAb. Moreover, our results showed that continuous clearance of soluble Aβ from the CSF for a few weeks decreases cortical Aβ plaques. Thus, we conclude that this intervention is feasible and may provide important advantages in terms of safety and efficacy.es_ES
dc.description.sponsorshipThis work was supported by the Instituto de Salud Carlos III, under Grant DTS19-00071 to M.M.-G. and by the Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología (FICYT), under Grant AYUD/2021/57540, to C.T.-Z.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es/
dc.subjectimmunotherapyes_ES
dc.subjectAlzheimeres_ES
dc.subjectbeta-amyloides_ES
dc.subjectCSF-sinkes_ES
dc.subjectcerebrospinal fluides_ES
dc.subjectimplantable devicees_ES
dc.subjectblood brain barrieres_ES
dc.subjectnanoporous membraneses_ES
dc.titleNew, Fully Implantable Device for Selective Clearance of CSF-Target Molecules: Proof of Concept in a Murine Model of Alzheimer’s Diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2022-08-25T11:19:48Z
dc.rights.holder© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/23/16/9256es_ES
dc.identifier.doi10.3390/ijms23169256
dc.departamentoesNeurociencias
dc.departamentoeuNeurozientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Except where otherwise noted, this item's license is described as © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).